Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Dynavax Technologies Corporation - Common Stock (NQ: DVAX )

13.69 -0.05 (-0.36%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dynavax Technologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
On Thursday, Rocket Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 88 to 94. 
Via Investor's Business Daily
Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90
On Monday, Kura Oncology stock had its Relative Strength (RS) Rating upgraded to 91, up from 85 a day earlier. 
Via Investor's Business Daily
Dynavax Technologies: Q2 Earnings Insights
Dynavax Technologies (NASDAQ:DVAX) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings
IBD 50 member Amphastar Pharmaceuticals stock is expected to report on Aug. 9 and is trading approximately 12% below a 42.41 entry. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers 
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating
Crispr Therapeutics sees its Relative Strength Rating enter the elite 90-plus level. 
Via Investor's Business Daily
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
The group has several commonalities, including strong ratings and promising charts. 
Via Investor's Business Daily
Prometheus Biosciences Stock Shows Rising Relative Strength
Prometheus Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 72 to 90. 
Via Investor's Business Daily
Merus Stock Joins Rank Of Stocks With RS Ratings Over 90
On Thursday, Netherlands-based Merus stock had its Relative Strength (RS) Rating upgraded to 94 from 78 a day earlier. 
Via Investor's Business Daily
Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
ApellisPharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level. 
Via Investor's Business Daily
Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90
On Monday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 91 Monday, up from 85 a day earlier. 
Via Investor's Business Daily
Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8%
Among its other key ratings, Amsterdam-based gene therapy company Uniqure stock also has a 92 Composite Rating. 
Via Investor's Business Daily
Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating
The Relative Strength (RS) Rating for Kezar Life Sciences stock jumped into a new percentile Friday, with a rise from 78 to 81. 
Via Investor's Business Daily
Apellis Pharmaceuticals Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Apellis Pharmaceuticals stock saw its Relative Strength (RS) Rating upgraded to 85 Friday, up from 79 a day earlier. 
Via Investor's Business Daily
7 Small-Cap Stocks to Buy in July 2022
These are the best small-cap stocks to buy for July 2022. ARCH, AVUV, CEIX, COUR, DVAX, FATE, and TENB can make great investments. 
Via InvestorPlace
110 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital. 
Via Benzinga
56 Stocks Moving In Friday's Mid-Day Session
Gainers Veru Inc. (NASDAQ: VERU) shares jumped 62.5% to $14.67 after the company reported quarterly results on Thursday. Jefferies maintained Veru with a Buy and raised the price target from $33 to... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
Dynavax's Adjuvant-Based Bivalent COVID-19 Vaccine Candidate Shows Encouraging Preclinical Action
Via Benzinga
Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from... 
Via FinancialNewsMedia
Dynavax Adjuvanted Clover Bio's COVID-19 Vaccine Booster Shows Durable Protection Against Omicron
Via Benzinga
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: Dynavax Technologies Q4 Earnings
Dynavax Technologies (NASDAQ:DVAX) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
A Preview Of Dynavax Technologies's Earnings
Dynavax Technologies (NASDAQ:DVAX) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Three doses of Valneva's COVID-19 Vaccine Neutralizes Omicron Variant, Lab Study Shows
Valneva SE (NASDAQ: VALN) has announced results from an initial laboratory study demonstrating that serum antibodies induced by three doses of Valneva's COVID-19 vaccine... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Tigress Financial lifted the price target on McDonald's Corporation (NYSE: 
Via Benzinga
Here's Why These 3 COVID-19 Vaccine Stocks Got Crushed This Week
These second-tier COVID-19 vaccine players plunged due to fears about the potential impacts of the omicron variant. 
Via The Motley Fool
Exposures COVID-19
Why Dynavax Stock Is Tumbling Today
The biotech stock is being pulled down by the broader market sell-off. 
Via The Motley Fool
Why Are Valneva Shares Trading Higher Today?
Valneva SE (NASDAQ: VALN) has signed an Advance Purchase Agreement (APA) with the European Commission (EC) to supply up to 60 million doses of its inactivated COVID... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.